26908-35-0

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(5-chloro-2-nitrophenyl)-1,3-dioxolane is utilized as an intermediate in the synthesis of various pharmaceutical compounds. Its electron-withdrawing properties contribute to the formation of new molecules with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 2-(5-chloro-2-nitrophenyl)-1,3-dioxolane is employed as a key component in the production of certain pesticides and herbicides. Its chemical properties allow for the creation of effective compounds that can protect crops from pests and weeds.
Used in Chemical Reactions:
2-(5-chloro-2-nitrophenyl)-1,3-dioxolane is used as a reagent in various chemical reactions due to its strong electron-withdrawing group. This feature makes it a valuable tool in the synthesis of complex organic molecules and the modification of existing compounds to enhance their properties or reactivity.

Upstream product

• 19693-75-5 2-methoxy-1,3-dioxolane 
• 6628-86-0 5-chloro-2-nitrobenzaldehyde 
• 587-04-2 m-Chlorobenzaldehyde 
• 107-21-1 ethylene glycol 
• 73033-58-6 5-chloro-2-nitrobenzyl alcohol 
• 2516-95-2 5-chloro-2-nitrobenzoic acid 

Downstream Products

• 113259-81-7 5-(N-morpholinyl)-2-nitrobenzaldehyde 
• 1312163-00-0 4-(3-((tert-butyldimethylsilyloxy)methyl)-4-nitrophenyl)morpholine 
• 1312162-94-9 2-((tert-butyldimethylsilyloxy)methyl)-4-morpholinoaniline 
• 1354826-21-3 N₁-methyl-N₁-(2-morpholinoethyl)-N₃-(4-(piperidin-1-yl)-2-(6-(trifluoromethyl)-1H-indole-2-carbonyl)phenyl)isophthalamide 2,2,2-trifluoroacetate 
• 1354826-31-5 N₁-methyl-N₁-(2-morpholinoethyl)-N₃-(2-(1-(phenylsulfonyl)-6-(trifluoromethyl)-1H-indole-2-carbonyl)-4-(piperidin-1-yl)phenyl)isophthalamide 
• 1354826-19-9 3-(3-((4-(piperidin-1-yl)-2-(6-(trifluoromethyl)-1H-indole-2-carbonyl)phenyl)-carbamoyl)-benzylthio)-propanoic acid 
• 1354826-28-0 methyl 3-(3-((4-(piperidin-1-yl)-2-(6-(trifluoromethyl)-1H-indole-2-carbonyl)phenyl)carbamoyl)benzylthio)propanoate 
• 1354826-26-8 methyl 3-(3-((2-(1-(phenylsulfonyl)-6-(trifluoromethyl)-1H-indole-2-carbonyl)-4-(piperidin-1-yl)phenyl)carbamoyl)benzylthio)propanoate 
• 1354826-25-7 (2-amino-5-(piperidin-1-yl)phenyl)-(1-(phenylsulfonyl)-6-(trifluoromethyl)-1H-indol-2-yl)methanone 
• 1354826-24-6 (2-nitro-5-(piperidin-1-yl)phenyl)(1-(phenylsulfonyl)-6-(trifluoromethyl)-1H-indol-2-yl)methanone 
• 1354826-23-5 (2-nitro-5-(piperidin-1-yl)phenyl)(1-(phenylsulfonyl)-6-(trifluoromethyl)-1H-indol-2-yl)methanol 
• 113259-79-3 5-(piperidin-1-yl)-2-nitrobenzaldehyde 
• 1002556-19-5 C₁₃H₁₈N₂O₄ 
• 1002556-18-4 4-(3-(1,3-dioxolan-2-yl)-4-nitrophenyl)morpholine 

Relevant academic research and scientific papers

2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS

The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/ or Pyk2 mediated disorder or disease.

COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT

Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically ac

Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R)

The discovery and synthesis of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor 1-receptor (IGF-1R) are presented. Installing amine containing side chains at the 4-position of pyridone ring significantly improved the

New safety-catch photolabile protecting group

Photolabile protecting groups have proven their usefulness on many occasions. Their versions as linkers are however less attractive, as robustness and real orthogonality become critical issues. Safety-catch systems, where a preliminary activation phase is necessary, circumvent the problem of premature cleavage. In this work, we introduce a new safety-catch photolabile protecting group, whose cleavage requires the simultaneous presence of light and a chemical promoter.

Inhibitors of Blood Platelet cAMP Phosphodiesterase. 3. 1,3-Dihydro-2H-imidazoquinolin-2-one Derivatives with Enhanced Aqueous Solubility

Two series of 1,3-dihydro-2H-imidazoquinolin-2-one derivatives incorporating an additional site for acid salt formation were synthesized and evaluated as inhibitors of human blood platelet cAMP phosphodiesterase (PDE) and ADP-induced platelet aggregation.The objective of this study was to identify compounds that blended potent biological activity with a satisfactory level of aqueous solubility.From a series of 7-aminoimidazoquinolin-2-ones, biological and physical properties were optimally combined in the 1-piperidinyl derivative 11c.However, this compound offered no significant advantage over earlier studied compounds as an antithrombotic agent in an animal model of small vessel thrombosis.A series of 7-alkoxy alkanoic piperazinamide derivatives, in which the additional basic nitrogen atom was remote from the heterocyclic nucleus and accomodated in a secondary binding region of the cAMP PDE enzyme, demonstrated greater intrinsic cAMP PDE inhibitory activity.Structural modifications of this series focused on variation of the piperazine substituent and side-chain length.The lipophilicity of the N-substituent influenced biological potency and aqueous solubility, with substituents of seven carbon atoms or less generally providing acceptable solubility properties.The N-(cyclohexylmethyl)piperazinamide 21h was identified from this series of compounds as a potent inhibitor of platelet cAMP PDE, IC50 = 0.4 nM and ADP-induced platelet aggregation, IC50 = 0.51 μM after a 3-min exposure and 0.1 μM after a 15-min exposure of platelet-rich plasma to the drug.Evaluation of 21h and representative analogues in vivo using a rabbit model of small vessel thrombosis revealed significantly greater antithrombotic efficacy compared to that of previously studied compounds with similar intrinsic biological activity measured in vitro but inferior aqueous solubility.

Inhibitors of Cyclic AMP Phosphodiesterase. 3. Synthesis and Biological Evaluation of Pyrido and Imidazolyl Analogues of 1,2,3,5-Tetrahydro-2-oxoimidazoquinazoline

Hybridization of structural elements of 1,2,3,5-tetrahydro-2-oxoimidazoquinazoline ring system common to the cyclic AMP (cAMP) phosphodiesterase (PDE) inhibitors lixazinone (RS-82856,1) and anagrelide (3) with complementary features of other PDE inhibitor cardiotonic agents prompted the design and synthesis of the title compounds 7a-d, 11, 12, and 13a,b.The necessary features of these compounds were determined within the framework of the proposed active-site models for the high affinity form of cAMP PDE inhibited by cGMP (type IV).Evaluation of these targets, both in vitro as inhibitors of platelet or cardiac type IV PDE or in vivo as inotropic agents in the pentobarbital-anesthetized dog model of congestive heart failure, showed that these structure possessed negligibly enhanced activities over the parent heterocyclic system, and remained significantly inferior to 1 in all respects.This difference is ascribed to the absence of the N-cyclohexyl-N-methylbutyramidyl-4-oxy side chain of 1.The proposal that the acidic lactam-type functionality, common to the type IV PDE inhibitor inotropic agents such as 4-6 and 8-10, mimics the polarizable cyclic phosphate moiety of cAMP suggested that the side chain of 1 may function as an effective surrogate for selected characteristics of the adenine portion of cAMP.However, the results of this study show that incorporation of adenine-like hydrogen-bonding functionalities common to other type IV PDE inhibitors into the 1,2,3,5-tetrahydro-2-oxoimidazoquinazoline system did not enhance activity to the levels observed for 1 analogues.These observations, coupled with the kinetic pattern of inhibition of type IV PDE observed for 1 and analogues, suggest that access to a secondary, lipophilic-tolerant binding site, possibly coincident with the adenine binding domain, and adjacent to the catalytic ribose-phosphate binding site of platelet and cardiac type IV PDE, is responsible for the increased potency of these compounds.

7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation

Novel series of 2,3-dihydro-2-oxo-1H-imidazo[4,5-b]quinolinyl amine derivatives of Formula STR1 wherein R1 is hydrogen, lower alkyl; R2 is hydrogen, lower alkyl, lower alkoxy, halogen; R3 is hydrogen, lower alkyl; R4 is hydrogen, lower alkyl, alkanoyl, phenylalkanoyl wherein phenyl is optionally substituted with halogen, lower alkyl, lower alkoxy; R3 and R4 are joined together to form morpholinyl, piperidinyl or pyrrolidinyl optionally substituted with --CO2 R5 or STR2 wherein R5 is hydrogen or lower alkyl, and R6 is hydrogen, lower alkyl, cycloalkyl; 4-R7 -piperazinyl wherein R7 is --CO2 R8 wherein R8 is lower alkyl, phenyl optionally substituted with up to 2 halogen, lower alkyl or lower alkoxy; phenylalkanoyl of 7 to 10 carbon wherein phenyl is unsubstituted or independently substituted with up to 2 halogen, lower alkyl, lower alkoxy. The compounds are cyclic AMP phosphodiesterase inhibitors and are particularly useful as inhibitors of blood platelet aggregation and/or as cardiotonic agents.